Luca Richeldi

List of Publications by Year in Descending Order

248 papers	25,164 citations	59 h-index	157 g-index
320 ext. papers	32,896 ext. citations	9.8 avg, IF	6.82 L-index

#	Paper	IF	Citations
248	Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosis.. *European Respiratory Journal*, **2022**,	13.6	
247	Epidemiology and Diagnosis of Idiopathic Pulmonary Fibrosis **2022**, 189-198		
246	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.. *American Journal of Respiratory and Critical Care Medicine*, **2022**, 205, e18-e47	10.2	38
245	Accuracy and Predictors of Success of EUS-B-FNA in the Diagnosis of Pulmonary Malignant Lesions: A Prospective Multicenter Italian Study.. *Respiration*, **2022**, 1-9	3.7	0
244	COVID-related fibrosis: insights into potential drug targets. *Expert Opinion on Investigational Drugs*, **2021**, 1-13	5.9	3
243	Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis. *Internal and Emergency Medicine*, **2021**, 16, 349-357	3.7	1
242	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. *Radiology*, **2021**, 298, 550-566	20.5	15
241	Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. *Respiratory Research*, **2021**, 22, 84	7.3	11
240	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. *Chest*, **2021**, 159, 1107-1125	5.3	15
239	An updated safety review of the drug treatments for idiopathic pulmonary fibrosis. *Expert Opinion on Drug Safety*, **2021**, 20, 1035-1048	4.1	2
238	Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?. *Cells*, **2021**, 10,	7.9	5
237	Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials. *Expert Opinion on Emerging Drugs*, **2021**, 26, 93-101	3.7	2
236	Looking Ahead: Interstitial Lung Disease Diagnosis and Management in 2030. *Clinics in Chest Medicine*, **2021**, 42, 375-384	5.3	0
235	Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative. *Chest*, **2021**,	5.3	4
234	Residual respiratory impairment after COVID-19 pneumonia. *BMC Pulmonary Medicine*, **2021**, 21, 241	3.5	5
233	Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 211-220	10.2	20
232	Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey. *Advances in Therapy*, **2021**, 38, 854-867	4.1	12

231	Ventilatory Support in Patients with COVID-19. *Advances in Experimental Medicine and Biology*, **2021**, 1318, 469-483	3.6	
230	Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. *European Respiratory Journal*, **2021**,	13.6	4
229	Bidirectional epithelial-mesenchymal crosstalk provides self-sustaining profibrotic signals in pulmonary fibrosis. *Journal of Biological Chemistry*, **2021**, 297, 101096	5.4	3
228	Telemedicine-enabled, Hotel-based Management of Patients with COVID-19: A Single-Center Feasibility Study. *Annals of the American Thoracic Society*, **2021**, 18, 1743-1746	4.7	
227	Phase three clinical trials in idiopathic pulmonary fibrosis. *Expert Opinion on Orphan Drugs*, **2021**, 9, 1-11	1.1	0
226	Post-COVID lung fibrosis: The tsunami that will follow the earthquake. *Lung India*, **2021**, 38, S41-S47	1.1	30
225	Advances with pharmacotherapy for the treatment of interstitial lung disease.. *Expert Opinion on Pharmacotherapy*, **2021**, 1-13	4	
224	Reply to Fenton : An Expanded COVID-19 Telemedicine Intermediate Care Model Using Repurposed Hotel Rooms. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 1192-1193	10.2	
223	Fibrotic Hypersensitivity Pneumonitis: Diagnosis and Management. *Lung*, **2020**, 198, 429-440	2.9	5
222	Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study. *Respirology*, **2020**, 25, 1274-1282	3.6	4
221	Challenges in COVID-19: is pulmonary thromboembolism related to overall severity?. *Infectious Diseases*, **2020**, 52, 585-589	3.1	3
220	Telemedicine-enabled Accelerated Discharge of Patients Hospitalized with COVID-19 to Isolation in Repurposed Hotel Rooms. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 508-510	10.2	10
219	Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study. *Respirology*, **2020**, 25, 1144-1151	3.6	3
218	The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. *Radiology*, **2020**, 296, 172-180	20.5	471
217	Possible Role of Chest Ultrasonography for the Evaluation of Peripheral Fibrotic Pulmonary Changes in Patients Affected by Idiopathic Pulmonary Fibrosis: Pilot Case Series. *Applied Sciences (Switzerland)*, **2020**, 10, 1617	2.6	2
216	Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. *Lancet Respiratory Medicine,the*, **2020**, 8, 453-460	35.1	154
215	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. *Lancet Respiratory Medicine,the*, **2020**, 8, 726-737	35.1	77
214	Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic. *Journal of Ultrasound*, **2020**, 23, 449-456	3.4	15

213	Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis. *Cell Death Discovery*, **2020**, 6, 54	6.9	6
212	Progressive Fibrosing Interstitial Lung Disease. A Proposed Integrated Algorithm for Management. *Annals of the American Thoracic Society*, **2020**, 17, 1199-1203	4.7	3
211	Antibody-based therapies for idiopathic pulmonary fibrosis. *Expert Opinion on Biological Therapy*, **2020**, 20, 779-786	5.4	6
210	Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. *BMC Pulmonary Medicine*, **2020**, 20, 3	3.5	29
209	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. *Chest*, **2020**, 157, 1506-1512	5.3	18
208	The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic: A Multinational Consensus Statement From the Fleischner Society. *Chest*, **2020**, 158, 106-116	5.3	384
207	Restless legs syndrome: A new comorbidity in idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2020**, 170, 105982	4.6	1
206	Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, **2020**, 37, 169-178	1.1	2
205	New Era of Management Concept on Pulmonary Fibrosis with Revisiting Framework of Interstitial Lung Diseases. *Tuberculosis and Respiratory Diseases*, **2020**, 83, 195-200	3.2	2
204	Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. *Expert Opinion on Investigational Drugs*, **2020**, 29, 771-777	5.9	15
203	Twenty-five years of Respirology: Advances in idiopathic pulmonary fibrosis. *Respirology*, **2020**, 25, 20-22	3.6	4
202	Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients. *Multiple Sclerosis and Related Disorders*, **2020**, 37, 101450	4	7
201	Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data. *Advances in Therapy*, **2020**, 37, 4209-4219	4.1	8
200	Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes?. *ERJ Open Research*, **2020**, 6,	3.5	5
199	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. *Lancet Respiratory Medicine,the*, **2020**, 8, 925-934	35.1	77
198	Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: relationships with disease progression and pulmonary function trends. *BMC Pulmonary Medicine*, **2020**, 20, 249	3.5	2
197	Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement. *Diagnostics*, **2020**, 10,	3.8	3
196	Treatment strategies for asthma: reshaping the concept of asthma management. *Allergy, Asthma and Clinical Immunology*, **2020**, 16, 75	3.2	11

195	Current Diagnosis and Management of Hypersensitivity Pneumonitis. *Tuberculosis and Respiratory Diseases*, **2020**, 83, 122-131	3.2	5
194	From pulmonary susceptible tuberculosis to extensively drug resistant tuberculosis: An interesting case report of a young Indian girl. *Indian Journal of Tuberculosis*, **2020**, 67, 340-342	1.6	1
193	Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet Respiratory Medicine,the*, **2020**, 8, 25-33	35.1	81
192	Which Biopsy to Diagnose Interstitial Lung Disease? A Call for Evidence and Unity. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 941-942	10.2	3
191	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. *New England Journal of Medicine*, **2019**, 381, 1718-1727	59.2	585
190	Subclinical Interstitial Lung Abnormalities: Lumping and Splitting Revisited. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 121-123	10.2	7
189	X-ray Micro-Computed Tomography for Nondestructive Three-Dimensional (3D) X-ray Histology. *American Journal of Pathology*, **2019**, 189, 1608-1620	5.8	24
188	Digital Lung Auscultation: Will Early Diagnosis of Fibrotic Interstitial Lung Disease Become a Reality?. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 261-263	10.2	3
187	The Fibrosis Across Organs Symposium: A Roadmap for Future Research Priorities. *American Journal of the Medical Sciences*, **2019**, 357, 405-410	2.2	0
186	Contemporary Concise Review 2018: Interstitial lung disease. *Respirology*, **2019**, 24, 809-816	3.6	3
185	New Frontiers in Ultrasonography of the Mediastinum: Pediatric EBUS-TBNA. *Respiratory Care*, **2019**, 64, 358-359	2.1	1
184	Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study. *European Respiratory Journal*, **2019**, 53,	13.6	0
183	Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 133-139	10.2	3
182	Update in Pulmonary Fibrosis 2018. *American Journal of Respiratory and Critical Care Medicine*, **2019** , 200, 292-300	10.2	6
181	Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. *ERJ Open Research*, **2019**, 5,	3.5	12
180	Educational interventions alone and combined with port protector reduce the rate of central venous catheter infection and colonization in respiratory semi-intensive care unit. *BMC Infectious Diseases*, **2019**, 19, 215	4	2
179	Current and Future Idiopathic Pulmonary Fibrosis Therapy. *American Journal of the Medical Sciences* , **2019**, 357, 370-373	2.2	8
178	Agreement between chest ultrasonography and chest X-ray in patients who have undergone thoracic surgery: preliminary results. *Multidisciplinary Respiratory Medicine*, **2019**, 14, 9	3	9

177	Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. *BMJ Open Respiratory Research*, **2019**, 6, e000397	5.6	66
176	Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS trials. *Respiratory Research*, **2019**, 20, 71	7.3	16
175	Novel drug targets in idiopathic pulmonary fibrosis. *Expert Opinion on Orphan Drugs*, **2019**, 7, 125-146	1.1	1
174	The characterisation of interstitial lung disease multidisciplinary team meetings: a global study. *ERJ Open Research*, **2019**, 5,	3.5	24
173	Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis. *Cell Death and Differentiation*, **2019**, 26, 943-957	12.7	49
172	Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. *Cell Death and Disease*, **2019**, 10, 591	9.8	59
171	Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib. *Respiratory Medicine*, **2019**, 156, 20-25	4.6	12
170	Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. *Lancet Respiratory Medicine,the*, **2019**, 7, 657-664	35.1	42
169	Statin Therapy and Lung Disorders. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 921-923	10.2	
168	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1146-1153	10.2	33
167	Pharmacologic Treatment of IPF. *Respiratory Medicine*, **2019**, 325-364	0.2	1
166	Idiopathic pulmonary fibrosis **2019**, 553-556		
165	Reply to Moodley and to Ravaglia et al. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 667-669	10.2	
164	Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis. *Expert Review of Respiratory Medicine*, **2019**, 13, 39-51	3.8	16
163	Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study. *European Respiratory Journal*, **2019**, 53,	13.6	6
162	No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone. *European Respiratory Journal*, **2019**, 53,	13.6	12
161	Lung function outcomes in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2019**, 146, 42-48	4.6	20
160	Diagnostic criteria for idiopathic pulmonary fibrosis - Authors' reply. *Lancet Respiratory Medicine,the*, **2018**, 6, e7	35.1	3

159	Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?. *Lancet Respiratory Medicine,the*, **2018**, 6, 154-160	35.1	76
158	Validation of multidisciplinary diagnosis in IPF. *Lancet Respiratory Medicine,the*, **2018**, 6, 88-89	35.1	10
157	Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. *Respiration*, **2018**, 95, 317-326	3.7	29
156	Nintedanib for the treatment of idiopathic pulmonary fibrosis. *Expert Opinion on Pharmacotherapy*, **2018**, 19, 167-175	4	36
155	Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. *Thorax*, **2018**, 73, 581-583	7.3	38
154	Do Randomized Clinical Trials Always Provide Certain Results? The Case of Tralokinumab in Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 9-10	10.2	4
153	Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 356-363	10.2	128
152	Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis. *European Journal of Heart Failure*, **2018**, 20, 1385-1391	12.3	24
151	"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease. *BMC Pulmonary Medicine*, **2018**, 18, 103	3.5	22
150	Ultrasonography of the Mediastinum: Techniques, Current Practice, and Future Directions. *Respiratory Care*, **2018**, 63, 1421-1438	2.1	5
149	Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 1105-1106	10.2	
148	Idiopathic pulmonary fibrosis: pathogenesis and management. *Respiratory Research*, **2018**, 19, 32	7.3	174
147	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 1036-1044	10.2	109
146	Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist. *Radiologia Medica*, **2018**, 123, 245-253	6.5	18
145	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respiratory Medicine,the*, **2018**, 6, 138-153	35.1	452
144	Management of Idiopathic Pulmonary Fibrosis **2018**, 55-63		1
143	Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. *ERJ Open Research*, **2018**, 4,	3.5	15
142	Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. *European Respiratory Review*, **2018**, 27,	9.8	50

141	Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers. *Chest*, **2018**, 154, 1359-1370	5.3	25
140	Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations. *Molecular Diagnosis and Therapy*, **2018**, 22, 723-728	4.5	8
139	Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis. *Current Pulmonology Reports*, **2018**, 7, 107-117	0.5	2
138	SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772). *European Respiratory Journal*, **2018**, 52,	13.6	41
137	Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. *New England Journal of Medicine*, **2018**, 379, 1722-1731	59.2	135
136	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, e44-e68	10.2	1426
135	Optimising experimental research in respiratory diseases: an ERS statement. *European Respiratory Journal*, **2018**, 51,	13.6	53
134	Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2018**, 319, 2299-2307	27.4	107
133	Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2018**, 52,	13.6	20
132	Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. *ELife*, **2018**, 7,	8.9	48
131	Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 78-85	10.2	108
130	Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. *Thorax*, **2017**, 72, 340-346	7.3	130
129	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1249-1254	10.2	105
128	Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies. *Respiration*, **2017**, 93, 379-395	3.7	17
127	Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2017**, 49,	13.6	74
126	New treatment directions for IPF: current status of ongoing and upcoming clinical trials. *Expert Review of Respiratory Medicine*, **2017**, 11, 533-548	3.8	9
125	Current approaches to the management of idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2017**, 129, 24-30	4.6	37
124	Idiopathic pulmonary fibrosis. *Lancet, The*, **2017**, 389, 1941-1952	40	617

123	Interstitial Lung Disease in India. Keep Searching and You'll Keep Finding. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 714-715	10.2	3
122	The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. *Lancet Respiratory Medicine,the*, **2017**, 5, 61-71	35.1	52
121	Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. *Clinical Infectious Diseases*, **2017**, 64, e1-e33	11.6	237
120	Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. *Clinical Infectious Diseases*, **2017**, 64, 111-115	11.6	336
119	Idiopathic pulmonary fibrosis. *Nature Reviews Disease Primers*, **2017**, 3, 17074	51.1	395
118	Challenges in idiopathic interstitial lung disease: an update **2017**, 56,		1
117	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *European Respiratory Journal*, **2017**, 50,	13.6	50
116	Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. *BMJ Open Respiratory Research*, **2017**, 4, e000212	5.6	107
115	Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?. *Expert Opinion on Pharmacotherapy*, **2017**, 18, 1583-1594	4	4
114	Investigational drugs for idiopathic pulmonary fibrosis. *Expert Opinion on Investigational Drugs*, **2017**, 26, 1019-1031	5.9	10
113	COPD management as a model for all chronic respiratory conditions: report of the 4 Consensus Conference in Respiratory Medicine. *Multidisciplinary Respiratory Medicine*, **2017**, 12, 28	3	1
112	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. *Lancet Respiratory Medicine,the*, **2017**, 5, 591-598	35.1	47
111	Individualizing duration of antibiotic therapy in community-acquired pneumonia. *Pulmonary Pharmacology and Therapeutics*, **2017**, 45, 191-201	3.5	6
110	PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients **2017**,		2
109	The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis. *Oncotarget*, **2017**, 8, 48737-48754	3.3	36
108	FVC decline over 1 year predicts mortality but not subsequent FVC decline in patients with IPF **2017**,		2
107	How we will diagnose IPF in the future. *QJM - Monthly Journal of the Association of Physicians*, **2016**, 109, 581-3	2.7	3
106	The safety of new drug treatments for idiopathic pulmonary fibrosis. *Expert Opinion on Drug Safety*, **2016**, 15, 1483-1489	4.1	15

105	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 265-75	10.2	653
104	Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 193, 1213-8	10.2	47
103	Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. *BMC Medicine*, **2016**, 14, 18	11.4	54
102	Novel drug targets for idiopathic pulmonary fibrosis. *Expert Review of Respiratory Medicine*, **2016**, 10, 393-405	3.8	16
101	Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 193, 178-85	10.2	169
100	Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. *JCI Insight*, **2016**, 1,	9.9	47
99	Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report. *Journal of Medical Case Reports*, **2016**, 10, 127	1.2	2
98	What if we made stratified medicine work for patients?. *Lancet Respiratory Medicine,the*, **2016**, 4, 8-10	35.1	9
97	Recent Advances and Future Needs in Interstitial Lung Diseases. *Seminars in Respiratory and Critical Care Medicine*, **2016**, 37, 477-84	3.9	3
96	Orphan Lung Diseases. *Seminars in Respiratory and Critical Care Medicine*, **2016**, 37, 319-20	3.9	
95	Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays. *New Microbes and New Infections*, **2016**, 12, 45-51	4.1	6
94	Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS( ) trials. *Respiratory Medicine*, **2016**, 113, 74-9	4.6	245
93	Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history. *Respirology*, **2016**, 21, 427-37	3.6	90
92	Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. *Lung India*, **2015**, 32, 50-2	1.1	24
91	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, e3-19	10.2	1122
90	Nintedanib in the treatment of idiopathic pulmonary fibrosis. *Therapeutic Advances in Respiratory Disease*, **2015**, 9, 121-9	4.9	46
89	Efficacy endpoints for idiopathic pulmonary fibrosis trials. *Lancet Respiratory Medicine,the*, **2015**, 3, 335-7	35.1	2
88	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. *European Respiratory Journal*, **2015**, 46, 243-9	13.6	35

87	Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy. *Pharmacology & Therapeutics*, **2015**, 152, 18-27	13.9	61
86	Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. *Respirology*, **2015**, 20, 389-94	3.6	4
85	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. *European Respiratory Journal*, **2015**, 46, 976-87	13.6	541
84	Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. *BMC Medicine*, **2015**, 13, 237	11.4	27
83	Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. *BMC Medicine*, **2015**, 13, 277	11.4	21
82	Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. *Respiratory Research*, **2015**, 16, 116	7.3	79
81	Reply: Weight-Loss Effect on FVC in Nintedanib Idiopathic Pulmonary Fibrosis Trials?. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 1020-1	10.2	
80	Acute myocardial infarction other cardiovascular events in community-acquired pneumonia. *ERJ Open Research*, **2015**, 1,	3.5	18
79	CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. *Lancet Respiratory Medicine,the*, **2015**, 3, 483-96	35.1	95
78	Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy. *BMJ Open Respiratory Research*, **2015**, 2, e000065	5.6	13
77	Effect of baseline FVC on lung function decline with nintedanib in patients with IPF **2015**,		6
76	Pulmonary Fibrosis and the Many Faces of UIP **2015**, 315-325		
75	Therapeutic approach and molecular targets for novel treatments **2015**, 176-195		
74	Time for Prevention of Idiopathic Pulmonary Fibrosis Exacerbation. *Annals of the American Thoracic Society*, **2015**, 12 Suppl 2, S181-5	4.7	9
73	Purpose of the Conference: 2015 Transatlantic Airway Conference. *Annals of the American Thoracic Society*, **2015**, 12, S111-S111	4.7	
72	Combination therapy: the future of management for idiopathic pulmonary fibrosis?. *Lancet Respiratory Medicine,the*, **2014**, 2, 933-942	35.1	97
71	Treatments for idiopathic pulmonary fibrosis. *New England Journal of Medicine*, **2014**, 371, 783	59.2	22
70	Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *New England Journal of Medicine*, **2014**, 370, 2071-82	59.2	2337

69	Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis. *Chest*, **2014**, 146, 1055-1063	5.3	32
68	A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM). *PLoS ONE*, **2014**, 9, e105365	3.7	9
67	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. *Thorax*, **2014**, 69, 428-36	7.3	75
66	Idiopathic pulmonary fibrosis: CT and risk of death. *Radiology*, **2014**, 273, 570-9	20.5	66
65	Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. *European Respiratory Review*, **2014**, 23, 106-10	9.8	49
64	Cross-disciplinary collaboration in connective tissue disease-related lung disease. *Seminars in Respiratory and Critical Care Medicine*, **2014**, 35, 159-65	3.9	23
63	Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2014**, 108, 1023-30	4.6	69
62	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis **2014**, 297-311		
61	Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. *Respiratory Research*, **2013**, 14, 73	7.3	136
60	An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 733-48	10.2	2176
59	Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2013**, 107, 249-55	4.6	64
58	Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. *Autoimmunity Reviews*, **2013**, 12, 374-9	13.6	40
57	The reply. *American Journal of Medicine*, **2013**, 126, e19	2.4	23
56	Idiopathic pulmonary fibrosis: recent trials and current drug therapy. *Respiration*, **2013**, 86, 353-63	3.7	26
55	Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. *Annals of Internal Medicine*, **2013**, 158, 641-9	8	327
54	A culture-proven case of community-acquired legionella pneumonia apparently classified as nosocomial: diagnostic and public health implications. *Case Reports in Medicine*, **2013**, 2013, 303712	0.7	7
53	Prevalence and prognosis of unclassifiable interstitial lung disease. *European Respiratory Journal*, **2013**, 42, 750-7	13.6	164
52	New approaches to the design of clinical trials in idiopathic pulmonary fibrosis. *Clinical Investigation* , **2013**, 3, 531-544		1

51	The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF)--practical implications. *Respiratory Research*, **2013**, 14 Suppl 1, S2	7.3	51
50	Recommendations on treatment for IPF. *Respiratory Research*, **2013**, 14 Suppl 1, S6	7.3	13
49	Clinical trials of investigational agents for IPF: a review of a Cochrane report. *Respiratory Research*, **2013**, 14 Suppl 1, S4	7.3	8
48	Clinical trials in idiopathic pulmonary fibrosis: where we have been and where we are going. *Current Respiratory Care Reports*, **2012**, 1, 216-223		
47	Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. *European Respiratory Review*, **2012**, 21, 147-51	9.8	16
46	Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. *Thorax*, **2012**, 67, 407-11	7.3	117
45	Sarcoidosis: challenging diagnostic aspects of an old disease. *American Journal of Medicine*, **2012**, 125, 118-25	2.4	32
44	The role of biomarkers in low respiratory tract infections. *European Journal of Internal Medicine*, **2012**, 23, 429-35	3.9	11
43	Genetic testing in diffuse parenchymal lung disease. *Orphanet Journal of Rare Diseases*, **2012**, 7, 79	4.2	5
42	Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. *Multidisciplinary Respiratory Medicine*, **2012**, 7, 42	3	34
41	Management of idiopathic pulmonary fibrosis. *Clinics in Chest Medicine*, **2012**, 33, 85-94	5.3	7
40	Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 712-5	10.2	78
39	Aortic pulse wave velocity measurement in systemic sclerosis patients. *Reumatismo*, **2012**, 64, 360-7	1.1	13
38	The big clinical trials in idiopathic pulmonary fibrosis. *Current Opinion in Pulmonary Medicine*, **2012**, 18, 428-32	3	27
37	An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 788-824	10.2	4665
36	Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. *New England Journal of Medicine*, **2011**, 365, 1079-87	59.2	728
35	Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. *Expert Review of Respiratory Medicine*, **2011**, 5, 473-81	3.8	23
34	La Cochrane-review. *Revue Des Maladies Respiratoires Actualites*, **2011**, 3, S114-S115	0	

33	Emerging drugs for idiopathic pulmonary fibrosis. *Expert Opinion on Emerging Drugs*, **2011**, 16, 341-62	3.7	19
32	Role of the quantiferon-TB test in ruling out pleural tuberculosis: a multi-centre study. *International Journal of Immunopathology and Pharmacology*, **2011**, 24, 159-65	3	11
31	Tuberculosis infection in foreign-born children: a screening survey based on skin and blood testing. *International Journal of Tuberculosis and Lung Disease*, **2011**, 15, 1182-4, i	2.1	5
30	Efficacy of hormonal suppression in a patient with chyluria due to lymphangioleiomyomatosis. *Multidisciplinary Respiratory Medicine*, **2011**, 6, 313-7	3	3
29	A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. *Tuberculosis*, **2011**, 91, 260-7	2.6	86
28	A decade of interferon-release assays: quest for the holy grail to diagnose latent infection with mycobacterium tuberculosis?. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 1732	10.2	1
27	Viruses and acute exacerbations of idiopathic pulmonary fibrosis: rest in peace?. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 1583-4	10.2	9
26	The complex interrelationships between chronic lung and liver disease: a review. *Journal of Viral Hepatitis*, **2010**, 17, 381-90	3.4	19
25	Unexpected identification of bilateral masses in an asymptomatic heavy smoker. *Thorax*, **2010**, 65, 846	7.3	
24	Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. *Scandinavian Journal of Rheumatology*, **2010**, 39, 155-9	1.9	2
23	Acute exacerbations of chronic obstructive pulmonary disease: are antibiotics needed?. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 102-3	10.2	6
22	Quantitative Pulmonary T-Cell Responses for the Diagnosis of Active Tuberculosis. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 289-290	10.2	1
21	Non-steroid agents for idiopathic pulmonary fibrosis. *The Cochrane Library*, **2010**, CD003134	5.2	66
20	Amyotrophic lateral sclerosis and sarcoidosis: a difficult differential diagnosis. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2010**, 11, 410-1		0
19	Performance of tests for latent tuberculosis in different groups of immunocompromised patients. *Chest*, **2009**, 136, 198-204	5.3	119
18	To BAL or not to BAL: is this a problem in diagnosing IPF?. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 180, 379-80; author reply 380	10.2	4
17	Diagnosing latent tuberculosis infection: guess who coming to dinner?. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 180, 1-2	10.2	3
16	Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 180, 666-73	10.2	103

15	Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection. *Archivum Immunologiae Et Therapiae Experimentalis*, **2009**, 57, 425-33	4	13
14	Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents. *Pediatrics*, **2009**, 123, e419-24	7.4	106
13	Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay. *Expert Review of Respiratory Medicine*, **2008**, 2, 253-60	3.8	10
12	Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. *Seminars in Respiratory and Critical Care Medicine*, **2008**, 29, 610-9	3.9	12
11	Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. *Lancet, The*, **2006**, 367, 1328-34	40	382
10	An update on the diagnosis of tuberculosis infection. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 174, 736-42	10.2	229
9	Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 172, 631-5	10.2	207
8	Chronic beryllium disease: a model for pulmonary sarcoidosis?. *Acta Biomedica*, **2005**, 76 Suppl 2, 11-4	3.2	5
7	T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 170, 288-95	10.2	104
6	Immunomodulatory agents for idiopathic pulmonary fibrosis. *Cochrane Database of Systematic Reviews*, **2003**, CD003134		44
5	Corticosteroids for idiopathic pulmonary fibrosis. *The Cochrane Library*, **2003**, CD002880	5.2	95
4	Interaction of genetic and exposure factors in the prevalence of berylliosis. *American Journal of Industrial Medicine*, **1997**, 32, 337-40	2.7	103
3	Interaction of genetic and exposure factors in the prevalence of berylliosis **1997**, 32, 337		3
2	IPF: treatment and prevention of pulmonary exacerbations199-223		
1	Key ongoing issues in trial design253-259		